Effect of a new functional CYP3A4 polymorphism on tacrolimus dose requirement and trough blood levels in stable renal transplant patients

被引：0
|
作者：
Elens, L. [1 ]
van Schaik, R. [1 ]
Panin, N. [2 ]
De Meyer, M. [3 ]
Wallemacq, P. [2 ]
Lison, D. [2 ]
Mourad, M. [3 ]
Haufroid, V [2 ]
机构：
[1] Erasmus MC, Rotterdam, Netherlands
[2] Catholic Univ Louvain, Louvain Ctr Toxicol & Appl Pharmacol, B-1200 Brussels, Belgium
[3] Clin Univ St Luc, Kidney & Pancreas Transplantat Unit, B-1200 Brussels, Belgium
来源：
THERAPEUTIC DRUG MONITORING | 2011年 / 33卷 / 04期
关键词：
CYP3A4; CYP3A5; tacrolimus; kidney transplantation; pharmacogenetics; pharmacokinetics; single nucleotide polymorphism;
D O I：
暂无
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：507 / 507
页数：1
相关论文
共 50 条
  • [31] THE EFFECT OF CYP3A4 AND CYP3A5 POLYMORPHISMS ON THE TACROLIMUS PLASMA CONCENTRATION IN CHINESE POST RENAL TRANSPLANT RECIPIENTS
    Wen, Gaiyan
    Yuan, Hong
    Xi, Lanyan
    Huang, Zhijun
    Li, Ying
    Lu, Yao
    JOURNAL OF HYPERTENSION, 2016, 34 : E300 - E300
  • [32] Combination of CYP3A4 measurement in vivo and genetic stratification for P-glycoprotein explains 71% of the variability of dose/weight normalized tacrolimus trough levels in renal transplant recipients.
    Lemahieu, WPD
    Maes, BD
    Verbeke, K
    Pierik, M
    Vanrenterghem, YF
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 390 - 391
  • [33] Influence of CYP3A4*22 and CYP3A5*3 genetic polymorphisms on tacrolimus pharmacokinetics in adult renal transplant patients
    Salvador, Pilar
    Outeda, Maria
    Pedreira, Isaura
    Fernandez, Constantino
    Alonso, Angel
    Martin, Isabel
    TRANSPLANTATION, 2016, 100 (07) : S709 - S709
  • [34] CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients
    Kurzawski, Mateusz
    Dabrowska, Justyna
    Dziewanowski, Krzysztof
    Domanski, Leszek
    Peruzynska, Magdalena
    Drozdzik, Marek
    PHARMACOGENOMICS, 2014, 15 (02) : 179 - 188
  • [35] No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin a trough concentrations or rejection incidence in stable renal transplant recipients
    von Ahsen, N
    Richter, M
    Grupp, C
    Ringe, B
    Oellerich, M
    Armstrong, VW
    CLINICAL CHEMISTRY, 2001, 47 (06) : 1048 - 1052
  • [36] IMPACT OF CYP3A5, CYP3A4 AND MDR1 GENE POLYMORPHISMS ON TROUGH CONCENTRATIONS OF TACROLIMUS, CYCLOSPORINE AND SIROLIMUS IN RENAL TRANSPLANT RECIPIENTS
    Shi, Yunying
    Li, Yi
    Cai, Bei
    Cai, Bei
    Zou, Yuangao
    Tao, Ye
    Wang, Lanlan
    TRANSPLANT INTERNATIONAL, 2013, 26 : 84 - 84
  • [37] Tacrolimus, but not cyclosporine, dose requirement is correlated with CYP3A5*3 and CYP3A4*1B genotype
    Hesselink, DA
    van Schaik, RHN
    Gregoor, PJHS
    Weimar, W
    van Gelder, T
    THERAPEUTIC DRUG MONITORING, 2003, 25 (04) : 514 - 514
  • [38] Tacrolimus, but not cyclosporine, dose requirement is correlated with CYP3A5*3 and CYP3A4*1B genotype
    Hesselink, DA
    van Schaik, RHN
    Gregoor, PJHS
    Weimar, W
    van Gelder, T
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (03) : 359 - 359
  • [39] Tacrolimus Trough Levels and Level-to-Dose Ratio in Stable Renal Transplant Patients Converted to a Once-Daily Regimen
    Mecule, A.
    Tinti, F.
    Poli, L.
    Bachetoni, A.
    Umbro, I.
    Nofroni, I.
    Lai, Q.
    Pretagostini, R.
    Berloco, P. B.
    Mitterhofer, A. P.
    TRANSPLANTATION PROCEEDINGS, 2011, 43 (04) : 1024 - 1027
  • [40] The effect of CYP3A5 and P-glycoprotein (MDR-1) polymorphisms on tacrolimus dose requirement in renal transplant patients
    Akbas, SH
    Keser, I
    Bilgen, T
    Tuncer, M
    Gultekin, M
    Luleci, G
    CLINICA CHIMICA ACTA, 2005, 355 : S196 - S196
12345